15 studies found for:    michaelson
Show Display Options
Rank Status Study
1 Recruiting Tivozanib + Enzalutamide in Adv Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Tivozanib;   Drug: Enzalutamide
2 Recruiting Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin acetate;   Drug: leuprolide acetate;   Drug: orteronel;   Drug: triptorelin
3 Recruiting Individually Tailored Web-based Multimodal Pain Rehabilitation in Primary Health Care
Condition: Musculoskeletal Pain
Intervention: Behavioral: Web-based multimodal rehabilitation based on cognitive based principles
4 Completed
Has Results
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: ET 743
5 Completed
Has Results
Study of SU11248 in Men With Advanced Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: Sunitinib
6 Completed Microculture Kinetic (MiCK) Apoptosis Test Results With Drug Treatment Results in Cancer Patients
Condition: Cancer
Intervention:
7 Completed Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
Conditions: Stage I Bladder Cancer;   Stage II Bladder Cancer;   Stage III Bladder Cancer;   Transitional Cell Carcinoma of the Bladder
Interventions: Drug: paclitaxel;   Biological: trastuzumab;   Radiation: radiation therapy
8 Withdrawn Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Interventions: Drug: Sunitinib;   Drug: Bevacizumab
9 Active, not recruiting Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Conditions: Renal Cell Carcinoma;   Neoplasm Metastases
Interventions: Drug: Gemcitabine;   Drug: Sunitinib
10 Recruiting Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
Condition: Pulmonary Arterial Hypertension
Intervention:
11 Recruiting Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: systemic chemotherapy;   Drug: tamoxifen citrate;   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment
12 Recruiting Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: docetaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Drug: paclitaxel;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
13 Recruiting Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Dovitinib;   Drug: Fulvestrant
14 Recruiting Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Condition: Hormone Receptor Positive Breast Cancer
Interventions: Drug: Everolimus;   Drug: Letrozole;   Drug: Exemestane;   Drug: Alcohol-free dexamethasone mouth rinse
15 Recruiting A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: TRC105 and Axitinib

Indicates status has not been verified in more than two years